(Reuters) -Sanofi plans to seek U.S. approval for its best-selling anti-inflammatory drug Dupixent to be used in the treatment of "smoker's lung", also known as COPD, after a second large trial showed ...
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...
May 31 (Reuters) - Sanofi (SASY.PA), opens new tab and partner Regeneron Pharmaceuticals (REGN.O), opens new tab have secured the European regulator's backing for use of Dupixent in patients with a ...
The eczema drug is already approved for patients 12 and older; this proposal would allow it to be prescribed to those as young as 6. Sanofi and Regeneron already market Dupixent in the U.S. for use by ...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...
TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing ...
Sanofi and Regeneron’s Dupixent is on fire. A week after scoring the first FDA approval for eosinophilic esophagitis, the drug scored priority review for prurigo nodularis. If it wins the agency's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback